Aethlon Medical Announces Publication of Preclinical Data Showing Ability of the Hemopurifier® to Remove Extracellular Vesicles and microRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Discarded Donor Kidneys

Stock Information for Aethlon Medical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aethlon Medical Inc.

Life Sciences Virtual Investor Forum Agenda Announced for September 19th
Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier® Cancer Trial
Aethlon Medical to Present at the Life Sciences Investor Forum September 19th
Aethlon Medical Announces Financial Results for the Fiscal First Quarter Ended June 30, 2024 and Provides Corporate Update
The Cancer Battle - How Smaller Companies Are Making Big Advancements in Treatments for Solid Tumors
Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier® Cancer Trial
Aethlon Medical to Release Fiscal First Quarter Financial Results and Host Conference Call on August 14, 2024
Aethlon Medical Announces Financial Results for the Fiscal Year Ended March 31, 2024 and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.